1 Thai, A. A., Solomon, B. J., Sequist, L. V., Gainor, J. F. & Heist, R. S. Lung cancer. The Lancet 398, 535-554, doi:10.1016/s0140-6736(21)00312-3 (2021).
2 Paz-Ares, L. et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med 379, 2040-2051, doi:10.1056/NEJMoa1810865 (2018).
3 Suzanne L. Topalian , Stephen Hodi. et al. safety activity and immune correlates of anti pd antibody. N Engl J Med,2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. (2012).
4 Weber, J. S., Yang, J. C., Atkins, M. B. & Disis, M. L. Toxicities of Immunotherapy for the Practitioner. J Clin Oncol 33, 2092-2099, doi:10.1200/JCO.2014.60.0379 (2015).
5 Xiang, L. et al. Computed Tomography-Guided Interstitial High-Dose-Rate Brachytherapy in Combination With Regional Positive Lymph Node Intensity-Modulated Radiation Therapy in Locally Advanced Peripheral Non-Small Cell Lung Cancer: A Phase 1 Clinical Trial. Int J Radiat Oncol Biol Phys 92, 1027-1034, doi:10.1016/j.ijrobp.2015.04.019 (2015).
6 Faivre-Finn, C. et al. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. J Thorac Oncol 16, 860-867, doi:10.1016/j.jtho.2020.12.015 (2021).
7 Hui, R. et al. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. The Lancet Oncology 20, 1670-1680, doi:10.1016/s1470-2045(19)30519-4 (2019).
8 Antonia, S. J. et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. New England Journal of Medicine 379, 2342-2350, doi:10.1056/NEJMoa1809697 (2018).
9 Durm, G. A. et al. A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179. Cancer 126, 4353-4361, doi:10.1002/cncr.33083 (2020).
10 Welsh, J. W. et al. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res 7, 1903-1909, doi:10.1158/2326-6066.CIR-18-0793 (2019).
11 Mo, H. et al. Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study. Br J Cancer 119, 538-545, doi:10.1038/s41416-018-0100-3 (2018).
12 Welsh, J. et al. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. J Immunother Cancer 8, doi:10.1136/jitc-2020-001001 (2020).
13 Theelen, W. S. M. E. et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. The Lancet Respiratory Medicine 9, 467-475, doi:10.1016/s2213-2600(20)30391-x (2021).
14 Voong, K. R. et al. Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer 20, e470-e479, doi:10.1016/j.cllc.2019.02.018 (2019).